Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

Clinical trial NCT07413354 · RECRUITING

Trial details

NCT number: NCT07413354
Sponsor: Tongji Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)

Start date: 2026-04-01
Primary completion: 2027-03-31
Enrollment: 94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.